RXRA and chronic myelogenous leukemia, BCR-ABL1 positive: Treatment with RXRA ligands (9cRA, acitretin, and bexarotene) improved IM IC-50 in-vitro in primary bulk cells obtained from imatinib naive CML patients (Figure 2C).